BeyondSpring Reports 2025 Year-End Financial Results
BeyondSpring announced strong 2025 year-end financial results highlighted by positive Phase 3 clinical data for Plinabulin in non-small cell lung cancer (NSCLC), including a statistically significant overall survival benefit. The company plans a confirmatory Phase 3 DUBLIN-4 trial and reported progress on SEED Therapeutics' first-in-human trial for…